In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of ...

The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

AI-powered chatbots will enhance HCP engagement, while comprehensive customer lifetime value prediction will enable more ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

Using artificial intelligence-powered software for screening electrocardiograms (ECGs) could deliver results more quickly and ...